Administration of Intranasal Insulin During Cardiopulmonary Resuscitation Improves Neurological Outcomes After Cardiac Arrest

Adam D. Chalek
Wayne State University, adam.chalek@med.wayne.edu

Tulasi R. Jinka
The University Of Michigan

Kathleen J. Maheras
The University Of Michigan

Joseph M. Wider
The University Of Michigan

Sarita Raghunayakula
The University Of Michigan

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs
See next page for additional authors
Part of the Medical Sciences Commons

Recommended Citation
Chalek, Adam D.; Jinka, Tulasi R.; Maheras, Kathleen J.; Wider, Joseph M.; Raghunayakula, Sarita; Liao, Jinhui; Qvigstad, Amanda; Anzell, Anthony R.; Gruley, Erin; Ren, Xiaodan; Zhang, Rui; Neumar, Robert W.; and Sanderson, Thomas H., "Administration of Intranasal Insulin During Cardiopulmonary Resuscitation Improves Neurological Outcomes After Cardiac Arrest" (2020). Medical Student Research Symposium. 23.
https://digitalcommons.wayne.edu/som_srs/23

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.
Authors

This research abstract is available at DigitalCommons@WayneState: https://digitalcommons.wayne.edu/som_srs/23
INTRODUCTION: Over 325,000 people die from cardiac arrest each year. Prognosis is poor and survivors typically experience persistent neurologic deficits. Currently, neuroprotective treatments to reduce brain injury in cardiac arrest survivors are limited and ineffective. This study evaluates the potential neuroprotection induced by high dose intranasal insulin (HD-IN-I) in a rodent model of asphyxial cardiac arrest.

METHODS: Male Long Evans rats were block randomized to sham-operated controls or 8-minute asphyxial cardiac arrest treated with placebo or HD-IN-I at the onset of CPR. To investigate mechanism of action, hippocampi were collected 30 minutes post-ROSC and analyzed by Western blot for phosphorylation of Akt. To assess long-term functional outcomes, neurobehavioral evaluation was conducted using neurologic function scores daily and Barnes maze, Rotarod, and passive avoidance on days 7-10 post-ROSC. Histologic quantification of surviving hippocampal CA1 pyramidal neurons was also conducted.

RESULTS: Hippocampal phospho-Akt/total Akt ratio increased 2-fold in the placebo group and 5.7-fold in HD-IN-I group relative to shams (p < 0.05). Rats treated with HD-IN-I had significantly improved performance on Rotarod, Barnes maze, and passive avoidance (p < 0.05). HD-IN-I had no significant effect on ROSC rate, 10-day survival, systemic glycemic response, or on the number of surviving CA1 pyramidal neurons compared to placebo treatment.

DISCUSSION: This study is the first to demonstrate that HD-IN-I administered at the onset of CPR, causes phosphorylation of brain Akt and results in significant neuroprotection. This primary work strongly suggests that intranasal insulin could be the first highly effective neuroprotective treatment for cardiac arrest patients.